-
Pfizer Full Year 2025 Financial Report
Pfizer
Pfizer’s 2025 financial results show a 2% decline in revenue, driven by lower COVID-19 product sales. Non-COVID products and a strong R&D pipeline drive growth. The company projects steady performance with key catalysts in 2026.
-
Global Biopharma Layoffs December 2025
Layoffs
This article tracks recent biotech and pharma layoffs, including major workforce cuts at Voyager Therapeutics, Intercept Pharmaceuticals, Mythic Therapeutics, Pfizer, and others, as companies restructure operations, streamline pipelines, and refocus resources amid shifting market conditions.
-
-
Pfizer 2025 H1 Report
Financial statements
Pfizer reported $28.4B in revenue for H1 2025, driven by $1.5B in ADC product sales and strong oncology growth. With $13B in BD firepower, Pfizer eyes long-term expansion across key therapeutic areas.
-
-
Pfizer's Strategic Bet on Bispecifics
Pfizer
Pfizer commits up to $6B for rights to SSGJ-707, a PD-1xVEGF bispecific, after in-depth due diligence in China. The asset is expected to complement Pfizer’s ADC portfolio and advance its oncology strategy.
-
-
Pfizer's Talzenna Label Bid Faces Setback
FDA
The FDA’s advisory committee unanimously rejected Pfizer’s proposal to expand Talzenna’s use for prostate cancer patients without HRR mutations, citing insufficient evidence from the TALAPRO-2 trial.
-
SK Bioscience Wins Key Patent Battle
SK Bioscience
SK Bioscience wins a key patent dispute against Pfizer in South Korea, enabling global exports of its 13-valent pneumococcal vaccine. The company plans expansion into Southeast Asia and Latin America while advancing next-gen vaccine R&D.
-
巨野县|
海伦市|
玉门市|
雅安市|
沅陵县|
广丰县|
西贡区|
岱山县|
新营市|
安远县|
榆林市|
闵行区|
浏阳市|
大兴区|
高青县|
勐海县|
侯马市|
三门峡市|
麻阳|
常州市|
琼结县|
临漳县|
开化县|
偃师市|
平塘县|
邮箱|
公主岭市|
长岛县|
田东县|
仲巴县|
曲麻莱县|
黄浦区|
太康县|
来宾市|
若尔盖县|
祁连县|
北辰区|
保定市|
康保县|
榆社县|
贡山|